CL2022001479A1 - Minitrampas de vegf y métodos de uso de las mismas. - Google Patents

Minitrampas de vegf y métodos de uso de las mismas.

Info

Publication number
CL2022001479A1
CL2022001479A1 CL2022001479A CL2022001479A CL2022001479A1 CL 2022001479 A1 CL2022001479 A1 CL 2022001479A1 CL 2022001479 A CL2022001479 A CL 2022001479A CL 2022001479 A CL2022001479 A CL 2022001479A CL 2022001479 A1 CL2022001479 A1 CL 2022001479A1
Authority
CL
Chile
Prior art keywords
methods
vegf minitraps
minitraps
vegf
disorders
Prior art date
Application number
CL2022001479A
Other languages
English (en)
Inventor
Joel Martin
Samuel Davis
Shawn Lawrence
Amy Johnson
Meghan Casey
Jaimie Mastrogiacomo
Shunhai Wang
Ning Li
Andrew Tustian
Ankit Vartak
Matthew Franklin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022001479A1 publication Critical patent/CL2022001479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona moléculas de minitrampa de VEGF y un método para tratar o prevenir trastornos angiogénicos tal como trastornos oculares angiogénicos y cáncer.
CL2022001479A 2019-12-06 2022-06-03 Minitrampas de vegf y métodos de uso de las mismas. CL2022001479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06

Publications (1)

Publication Number Publication Date
CL2022001479A1 true CL2022001479A1 (es) 2023-01-20

Family

ID=74046173

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001479A CL2022001479A1 (es) 2019-12-06 2022-06-03 Minitrampas de vegf y métodos de uso de las mismas.

Country Status (13)

Country Link
US (1) US20230063116A1 (es)
EP (1) EP4069264A1 (es)
JP (1) JP2023505216A (es)
KR (1) KR20220110555A (es)
CN (1) CN114786695A (es)
AU (1) AU2020397053A1 (es)
BR (1) BR112022010686A2 (es)
CA (1) CA3163876A1 (es)
CL (1) CL2022001479A1 (es)
CO (1) CO2022008799A2 (es)
IL (1) IL293286A (es)
MX (1) MX2022006751A (es)
WO (1) WO2021113591A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
WO2012097019A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US11266745B2 (en) * 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .

Also Published As

Publication number Publication date
CN114786695A (zh) 2022-07-22
CA3163876A1 (en) 2021-06-10
KR20220110555A (ko) 2022-08-08
IL293286A (en) 2022-07-01
JP2023505216A (ja) 2023-02-08
AU2020397053A1 (en) 2022-06-23
EP4069264A1 (en) 2022-10-12
US20230063116A1 (en) 2023-03-02
CO2022008799A2 (es) 2022-06-30
BR112022010686A2 (pt) 2022-08-23
WO2021113591A1 (en) 2021-06-10
MX2022006751A (es) 2022-08-19

Similar Documents

Publication Publication Date Title
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112018011709A2 (pt) inibidores bicíclicos de pad4
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
EA201991818A1 (ru) Лечение рака
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
PH12018502154A1 (en) Methods of treating ocular conditions
BR112018007566A2 (pt) neuromodulação periférica dependente do estado para tratar disfunção da bexiga
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ZA202103975B (en) Methods of treating disease with magl inhibitors
BR112017025263A2 (pt) método para o tratamento de doença neurológica
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
CL2022001479A1 (es) Minitrampas de vegf y métodos de uso de las mismas.
MX2019010060A (es) Composiciones y metodo para tratar cancer.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.